290 related articles for article (PubMed ID: 19627018)
41. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
42. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk].
Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765
[No Abstract] [Full Text] [Related]
43. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis.
Umeda Y; Demura Y; Morikawa M; Anzai M; Kadowaki M; Ameshima S; Tsuchida T; Tsujikawa T; Kiyono Y; Okazawa H; Ishizaki T; Ishizuka T
J Nucl Med; 2015 Dec; 56(12):1869-75. PubMed ID: 26359263
[TBL] [Abstract][Full Text] [Related]
45. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Matsunaga N
Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249
[TBL] [Abstract][Full Text] [Related]
46. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease.
Cui J; Zhao P; Ren Z; Liu B
Medicine (Baltimore); 2015 Aug; 94(33):e1356. PubMed ID: 26287421
[TBL] [Abstract][Full Text] [Related]
48.
Abadi P; Johansen A; Godballe C; Gerke O; Høilund-Carlsen PF; Thomassen A
Ann Nucl Med; 2017 Feb; 31(2):101-108. PubMed ID: 27921286
[TBL] [Abstract][Full Text] [Related]
49. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
50. Differentiation of benign from malignant cervical lymph nodes in patients with head and neck cancer using PET/CT imaging.
Payabvash S; Meric K; Cayci Z
Clin Imaging; 2016; 40(1):101-5. PubMed ID: 26454617
[TBL] [Abstract][Full Text] [Related]
51. Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?
Yen TC; Chang YC; Chan SC; Chang JT; Hsu CH; Lin KJ; Lin WJ; Fu YK; Ng SH
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):541-8. PubMed ID: 15625603
[TBL] [Abstract][Full Text] [Related]
52. [The usefulness of FDG-PET in patients with cervical lymphadenopathy].
Chang P; Liu HC; Tian JH; Yao SL; Wang T
Zhonghua Kou Qiang Yi Xue Za Zhi; 2004 Nov; 39(6):449-51. PubMed ID: 15854311
[TBL] [Abstract][Full Text] [Related]
53. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5.
Macdonald K; Searle J; Lyburn I
Clin Radiol; 2011 Mar; 66(3):244-50. PubMed ID: 21295203
[TBL] [Abstract][Full Text] [Related]
54. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
55. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2010 Mar; 116(6):1469-75. PubMed ID: 20108309
[TBL] [Abstract][Full Text] [Related]
56. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
57. Dual-time point positron emission tomography findings of benign mediastinal lymph nodes in a tuberculosis-endemic region.
Kim DW; Kim CG
Jpn J Radiol; 2011 Dec; 29(10):682-7. PubMed ID: 22009418
[TBL] [Abstract][Full Text] [Related]
58. 18F-FDG PET/CT makes a significant contribution to diagnosis of malignancy in patients with cervical lymphadenopathy: a study using optimal scale regression tests.
Ouyang L; Shi ZY; Lin ZG
Chin Med J (Engl); 2013 Feb; 126(4):659-67. PubMed ID: 23422185
[TBL] [Abstract][Full Text] [Related]
59. Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies.
Yamamoto Y; Wong TZ; Turkington TG; Hawk TC; Coleman RE
Radiology; 2007 Jul; 244(1):263-72. PubMed ID: 17495174
[TBL] [Abstract][Full Text] [Related]
60. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
